Valuation
- Market cap
- 12,764,000
- Revenue TTM
- $0
- Net income TTM
- $-75,800,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 10,900
- Avg volume
- 18,548
- Day's range
- $10.61 – $11.50
- Shares out
- 1,108,000
- Stochastic %K
- 19%
- Beta
- 3.30
- Analysts
- Moderate Buy
- Price target
- $89.83
Company profile
Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. Its products in various stages of development include KP-104, a dual-complement inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) which is in Phase 2; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditionin...
Show more
Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. Its products in various stages of development include KP-104, a dual-complement inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) which is in Phase 2; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders. The company is headquartered in Redwood City, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 650-549-1400
- Website
- https://jaspertx.com
- Address
- 2200 Bridge Pkwy, Suite #102, Redwood City, United States
Latest news
No headlines yet.